Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia

Blood

Volumn 125, Issue 20, 2015, Pages 3128-3132

  Hing, Zachary A ^a,b   Mantel, Rose ^b   Beckwith, Kyle A ^a,b   Guinn, Daphne ^b   Williams, Erich ^b   Smith, Lisa L ^b   Williams, Katie ^b   Johnson, Amy J ^a,b   Lehman, Amy M ^a   Byrd, John C ^a,b   Woyach, Jennifer A ^b   Lapalombella, Rosa ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IBRUTINIB; SELINEXOR; ANTINEOPLASTIC AGENT; HYDRAZINE DERIVATIVE; KPT-330; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ISOLATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; GENE MUTATION; HUMAN; HUMAN CELL; IN VIVO STUDY; LYMPHOCYTOSIS; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIMARY CELL; PRIORITY JOURNAL; ANIMAL; CELL SURVIVAL; DISEASE MODEL; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MORTALITY; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; HYDRAZINES; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MICE; PYRAZOLES; PYRIMIDINES; TRIAZOLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84964694021     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-01-621391     Document Type: Article

References (20)

1. Woyach JA, Furman RR, Liu TM, et al. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N Engl J Med. 2014;370(24): 2286-2294.
2. Woyach JA, Ruppert AS, Lozanski G, et al. Association of disease progression on ibrutinib therapy with the acquisition of resistance mutations: a single-center experience of 267 patients. J Clin Oncol. 2014;32:15s. Abstract 7010.
3. Mohamed AJ, Yu L, Bäckesjö C-M, et al. Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain. Immunol Rev. 2009;228(1):58-73.
4. Cinar M, Hamedani F, Mo Z, Cinar B, Amin HM, Alkan S. Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis. Leuk Res. 2013;37(10):1271-1277.
5. Wilson WH, Gerecitano JF, Goy A, et al. The Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the ABC subtype of relapsed/refractory de novo diffuselarge B-cell lymphoma (DLBCL): interim results of a multicenter, open-label, phase 2 Study [abstract]. Blood. 2012;120(21). Abstract 686.
6. Yang Y, Shaffer AL III, Emre NC, et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell. 2012;21(6): 723-737.
7. Byrd JC, Brown JR, O'Brien S, et al; RESONATE Investigators. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213-223.
8. Furman RR, Cheng S, Lu P, et al. Ibrutinib resistance in chronic lymphocytic leukemia. N Engl J Med. 2014;370(24):2352-2354.
9. Xu D, Grishin NV, Chook YM. NESdb: a database of NES-containing CRM1 cargoes. Mol Biol Cell. 2012;23(18):3673-3676.
10. Brennan CM, Gallouzi I-E, Steitz JA. Protein ligands to HuR modulate its interaction with target mRNAs in vivo. J Cell Biol. 2000;151(1):1-14.
11. Lapalombella R, Sun Q, Williams K, et al. Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia. Blood. 2012;120(23):4621-4634.
12. Kuruvilla J, Gutierrez M, Shah BD, et al. Preliminary evidence of antitumor activity of Selinexor (KPT-330) in a phase I trial of a first-in-class oral selective inhibitor of nuclear export (SINE) in patients (pts) with relapsed/refractory non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL) [abstract]. Blood. 2013;122(21). Abstract 90.
13. Chen CI, Gutierrez M, de Nully Brown P, et al. Antitumor activity of Selinexor (KPT-330), a firstin-class oral selective inhibitor of nuclear export (SINE) XPO1/CRM1 antagonist in patients (pts) with relapsed/refractory multiple myeloma (MM) or Waldenstrom's macroglobulinemia (WM) [abstract]. Blood. 2013;122(21). Abstract 1942.
14. Savona M, Garzon R, de Nully Brown P, et al. Phase I trial of selinexor (KPT-330), a first-inclass oral selective inhibitor of nuclear export (SINE) in patients (pts) with advanced acute myelogenous leukemia (AML) [abstract]. Blood. 2013;122(21). Abstract 1440.
15. Zhong Y, El-Gamal D, Dubovsky JA, et al. Selinexor suppresses downstream effectors of B-cell activation, proliferation and migration in chronic lymphocytic leukemia cells. Leukemia. 2014;28(5):1158-1163.
16. Lapalombella R, Yeh Y-Y, Wang L, et al. Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals. Cancer Cell. 2012;21(5):694-708.
17. Roecklein BA, Torok-Storb B. Functionally distinct human marrow stromal cell lines immortalized by transduction with the human papilloma virus E6/E7 genes. Blood. 1995;85(4):997-1005.
18. Kay NE, Shanafelt TD, Strege AK, Lee YK, Bone ND, Raza A. Bone biopsy derived marrow stromal elements rescue chronic lymphocytic leukemia B-cells from spontaneous and drug induced cell death and facilitates an "angiogenic switch". Leuk Res. 2007;31(7): 899-906.
19. Woyach JA, Bojnik E, Ruppert AS, et al. Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL). Blood. 2014;123(8): 1207-1213.
20. Woyach JA, Smucker K, Smith LL, et al. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood. 2014;123(12): 1810-1817.